Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TYMS | P04818 | 11/20 | 0.57 |
| ▸ | QTRT1 | Q9BXR0 | 1/20 | 0.54 |
| ▸ | PARP1 | P09874 | 5/20 | 0.49 |
| ▸ | XDH | P47989 | 1/20 | 0.45 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.45 |
| ▸ | TNKS | O95271 | 4/20 | 0.42 |
| ▸ | TNKS2 | Q9H2K2 | 4/20 | 0.42 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15228758 | 0.79 | PARP1 (0.49) | TYMSPARP1DYRK1ATNKSTNKS2 | |
| SCHEMBL4313736 | 0.79 | PARP1 (0.70) | TYMSQTRT1PARP1TNKSTNKS2 | |
| SCHEMBL30900892 | 0.79 | PARP1 (0.70) | TYMSPARP1TNKSTNKS2PARP2 | |
| SCHEMBL6931033 | 0.79 | PARP1 (0.70) | TYMSPARP1TNKSTNKS2PARP2 | |
| SCHEMBL15857995 | 0.76 | TNKS (0.67) | TYMSQTRT1PARP1TNKSTNKS2 | |
| SCHEMBL18341309 | 0.76 | TYMS (0.50) | TYMSQTRT1PARP1DYRK1ATNKS | |
| SCHEMBL17276019 | 0.74 | NUDT1 (0.51) | TYMSDYRK1A | |
| SCHEMBL6648915 | 0.73 | TYMS (1.00) | TYMS | |
| SCHEMBL14080068 | 0.72 | TYMS (0.70) | TYMSQTRT1 | |
| SCHEMBL15846636 | 0.72 | TYMS (0.57) | TYMSQTRT1PARP1TNKSTNKS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3313828-B1 | METALLO-BETA-LACTAMASE INHIBITORS | MERCK SHARP & DOHME LLC (US) | 2023-07-12 | — | — | EP | disclosed |
| US-10227331-B2 | Metallo-β-lactamase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2019-03-12 | — | — | US | disclosed |
| US-20180179190-A1 | METALLO-BETA-LACTAMASE INHIBITORS | Marck Sharp & Dohme Corp. (US) | 2018-06-28 | — | — | US | disclosed |
| EP-3313828-A1 | METALLO-BETA-LACTAMASE INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2018-05-02 | — | — | EP | disclosed |
| WO-2016206101-A1 | METALLO-BETA-LACTAMASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2016-12-29 | — | — | WO | disclosed |
| WO-2016210234-A1 | METALLO-BETA-LACTAMASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2016-12-29 | — | — | WO | disclosed |
| EP-2270002-A1 | Quinazoline derivatives as histamine H4-receptor inhibitors for use in the treatment of inflammatory disorders | Vereniging voor Christelijk Hoger Onderwijs, Wetenschappelijk Onderzoek en Patiëntenzorg (NL) | 2011-01-05 | — | — | EP | disclosed |
| WO-2010146173-A1 | QUINAZOLINE DERIVATIVES AS HISTAMINE H4-RECEPT0R INHIBITORS FOR USE IN THE TREATMENT OF INFLAMMATORY DISORDERS | VERENIGING VOOR CHRISTELIJK HOGER ONDERWIJS, WETENSCHAPPELIJK ONDERZOEK EN PATIENTENZORG (NL) | 2010-12-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10227331-B2 | Metallo-β-lactamase inhibitors | ALPI, GAA, ZFX | TYMS 2550/4885QTRT1 472/4885PARP1 1915/4885 |
| US-20180179190-A1 | METALLO-BETA-LACTAMASE INHIBITORS | ALPI, GAA, ZFX | TYMS 2538/4885QTRT1 448/4885PARP1 1933/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.